Jove
Visualize
Contact Us

Related Experiment Videos

Maintenance immunosuppression.

S K Takemoto

    Clinical Transplants
    |August 22, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Newer immunosuppressants like Neoral and Tacrolimus significantly reduced kidney transplant rejection rates in the 1990s. Mycophenolate mofetil further decreased graft loss and mortality compared to older treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
    Same author

    Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
    Same author

    A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
    Same author

    Patient and graft survival implications of simultaneous pancreas kidney transplantation from old donors.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
    Same author

    Lack of interventional studies in renal transplant candidates with elevated cardiovascular risk.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
    Same author

    Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches.

    Transplantation proceedings·2005
    Same journal

    Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.

    Clinical transplants·2017
    Same journal

    Influenza Immunization and the Generation of Anti-HLA and Anti-MICA Antibodies in Patients with Renal Failure and in Kidney Transplant Recipients.

    Clinical transplants·2017
    Same journal

    From Accurate Assessment of Anti-HLA Antibody MFI to Complement-Binding Assays.

    Clinical transplants·2017
    Same journal

    Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.

    Clinical transplants·2017
    Same journal

    Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD).

    Clinical transplants·2017
    Same journal

    C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.

    Clinical transplants·2017
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Nephrology
    • Immunology
    • Transplantation Medicine

    Background:

    • Kidney transplant outcomes have historically been limited by rejection and graft loss.
    • The 1990s saw significant advancements in immunosuppressive therapies.
    • Understanding the impact of these new agents on transplant success is crucial.

    Purpose of the Study:

    • To evaluate the impact of novel immunosuppressive drugs on renal transplant rejection rates.
    • To compare the efficacy and safety of Neoral and Tacrolimus.
    • To assess the role of mycophenolate mofetil and corticosteroids in transplant outcomes.

    Main Methods:

    • Retrospective analysis of renal transplant recipients from the 1990s.
    • Comparison of rejection rates and graft survival based on different immunosuppressive regimens.

    Related Experiment Videos

  • Multivariate analysis to assess the odds ratio of rejection and graft loss.

    • Main Results:

    • Increased use of Neoral, Tacrolimus, and mycophenolate mofetil correlated with decreased rejection rates.
    • Tacrolimus showed a slightly higher rejection incidence (20%) than Neoral (16%), with similar graft loss and mortality risks.
    • Mycophenolate mofetil significantly reduced 3-year graft loss (by 60%) and mortality (by 50%) compared to azathioprine.
    • Corticosteroid (Solumedrol) use increased without significant outcome impact.
    • Induction therapies (ATG, OKT3) were associated with increased graft failure risk, often in high-risk patients.
    • Higher HLA mismatches (5-6) increased rejection risk by 90% and graft loss by 50%.

    Conclusions:

    • Neoral and Tacrolimus represent significant improvements in kidney transplant immunosuppression.
    • Mycophenolate mofetil is a highly effective agent for reducing graft loss and mortality.
    • HLA matching remains a critical factor in long-term transplant success.